Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Notes Payables (2016 - 2020)

Historic Notes Payables for Zevra Therapeutics (ZVRA) over the last 6 years, with Q3 2020 value amounting to $65.9 million.

  • Zevra Therapeutics' Notes Payables rose 88124.44% to $65.9 million in Q3 2020 from the same period last year, while for Sep 2020 it was $65.9 million, marking a year-over-year increase of 88124.44%. This contributed to the annual value of $7.0 million for FY2019, which is 10944.57% up from last year.
  • Per Zevra Therapeutics' latest filing, its Notes Payables stood at $65.9 million for Q3 2020, which was up 88124.44% from $67.3 million recorded in Q2 2020.
  • Zevra Therapeutics' Notes Payables' 5-year high stood at $68.6 million during Q1 2020, with a 5-year trough of $1.6 million in Q1 2016.
  • For the 4-year period, Zevra Therapeutics' Notes Payables averaged around $18.9 million, with its median value being $6.4 million (2019).
  • Per our database at Business Quant, Zevra Therapeutics' Notes Payables surged by 9111.91% in 2019 and then surged by 97701.73% in 2020.
  • Zevra Therapeutics' Notes Payables (Quarter) stood at $1.9 million in 2016, then skyrocketed by 72.52% to $3.3 million in 2018, then soared by 109.45% to $7.0 million in 2019, then skyrocketed by 844.3% to $65.9 million in 2020.
  • Its Notes Payables was $65.9 million in Q3 2020, compared to $67.3 million in Q2 2020 and $68.6 million in Q1 2020.